Healthcare >> Analyst Interviews >> March 16, 2018

Gene Editing Companies Have Long-Term Potential to Be M&A Targets

Amusa, Gbola
Gbola Amusa is Partner, Director of Research and Head of Healthcare Research of Chardan. Dr. Gbola Amusa joined Chardan at the end of 2014 to focus on identifying companies that will generate exceptionally high long-term investment returns by creating shared value for society. Dr. Amusa was previously Managing Director, Head of European Pharma Research, and Global Pharma and Biotech Coordinator at UBS, where he oversaw 25 analysts and ultimately finished as the number-one-ranked European pharma analyst in the Institutional Investor — II — Survey. Prior to UBS, Dr. Amusa was a Senior Research Analyst and Head of European Pharma research at Sanford Bernstein. He started his career in finance at Goldman Sachs as an associate in the Healthcare Investment Banking Group, where he worked on large transactions including the Amgen/Immunex merger. Additionally, Dr. Amusa was previously a health care finance and strategy consultant working with governments, companies, leading foundations and think tanks. Dr. Amusa’s views on health care have been cited by socially responsible investing, or SRI; ESG; and sustainability organizations like FSG/Shares Value Initiative, GMI Ratings and the ATM Index. Dr. Amusa earned his BSE from Duke University, an M.D. at Washington University Medical School and his MBA from the University of Chicago Booth School of Business. Profile
TWST: Given that you have particular insights with your background in medicine, how does gene editing and gene therapy fit in the broader context of biotech as an investment